Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
ONLS
АТХ:N.06.A.X Other antidepressants
Pharmacodynamics:Indiscriminately inhibits the reverse neuronal seizure of serotonin and norepinephrine from the synaptic cleft. This leads to an increase in their concentrations in the post-synaptic receptor region and relief of symptoms of depression.
Pharmacokinetics:After oral administration, it is quickly and completely absorbed from the gastrointestinal tract. Bioavailability is about 80%. The maximum concentration in the blood is reached after 2 hours. Binding to plasma proteins is about 90%. Undergoes biotransformation in the liver with the formation of inactive metabolites. The half-life is 16 hours. Excreted mainly by the kidneys.
Indications:Depression (astheno-depressive syndrome, anxiety-depressive state, alcoholic depression, endogenous depression, exogenous depression, depressive states in chronic somatic diseases).
V.F30-F39.F32 Depressive episode
V.F30-F39.F33 Recurrent depressive disorder
Contraindications:Hepatic and / or renal insufficiency.Chronic heart failure.
Myocardial infarction.
Cardiac ischemia.
Condition after a stroke.
Infectious diseases.
Diabetes.
Pregnancy.
Lactation.
Simultaneous administration of MAO inhibitors.
Individual intolerance.
Carefully:Children's age (there is no information on the safety of use in children).
Pregnancy and lactation:The FDA action category is not defined. Contraindicated in pregnancy and breastfeeding.
Dosing and Administration:The initial dose for adults is 25-50 mg in 2 divided doses (morning and lunch). With good tolerability, the dose is gradually increased to 150-200 mg per day, and in some cases up to 400 mg per day. When the desired effect is achieved, they pass to maintenance doses of 25-75 mg per day. The duration of treatment is at least 1-1.5 months.
Side effects:Nervous system: headache, dizziness.Gastrointestinal tract: nausea, vomiting.
Allergic reactions.
Overdose:No data. Treatment is symptomatic.
Interaction:Potentiates the effects of alcohol and other drugs that depress the central nervous system, antihistamines. Reduces the effectiveness of anticonvulsant therapy.
Special instructions:After transfer from therapy with MAO inhibitors to pipethiazine an interval of 2 weeks is necessary. Periodic monitoring of liver and kidney function is necessary. During the period of treatment, alcohol is not allowed.